Safety of percutaneous ethanol injection as neoadjuvant therapy for hepatocellular carcinoma in waiting list liver transplant candidates

被引:26
作者
Castroagudín, JF [1 ]
Delgado, M [1 ]
Villanueva, A [1 ]
Bustamante, M [1 ]
Martínez, J [1 ]
Otero, E [1 ]
Tomé, S [1 ]
Martínez, SM [1 ]
Segade, FR [1 ]
Conde, R [1 ]
Dominguez-Muñoz, E [1 ]
Varo, E [1 ]
机构
[1] Univ Hosp Santiago De Compostela, Liver Transplant Unit, Santiago De Compostela, Spain
关键词
D O I
10.1016/j.transproceed.2005.09.168
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
Orthotopic liver transplantation (OLT) as therapy of hepatocellular carcinoma (HCC) improves the survival of a selected group of patients. Unfortunately, the progressive increase in waiting time for OLT may allow tumor progression. Percutaneous ethanol injection (PEI) has been proposed as neoadjuvant therapy for HCC in patients awaiting OLT, but its safety has not been defined. Patients and Methods. During a 60-month period, 34 patients (27 men, overall mean age of 58.5 years, range 41-67) with HCC, were listed for OLT. Ultrasonography-guided PEI was delivered into 39 nodules at 117 sessions on an inpatient basis. Written informed consent was obtained from all patients before PEI. Doppler-ultrasonography was done before PEI, immediately after, and 4 weeks later. Noninvasive monitoring of arterial pressure, cardiac rate, and temperature was performed during the procedure and during a 24-hour period after each session. Pain was considered significant if analgesia was required or discontinuation of PEI necessary. Fever was defined as a temperature >= 37.5 degrees C after PEI. Results. Minor complications included pain in 45 sessions (38.5%), fever in 17 (14.5%), arterial hypertension in 14 (12%), hypotension in 7 (7%), and vomiting in 2 (1.7%). The major complications were segmental liver infarction (n = 3), portal branch venous thrombosis (n = 2), ascites (n = 2), and one case each of subcapsular hematoma, duodenal ulcer, pneumonia, hepatic encephalopathy, and hepatic artery thrombosis. In all cases, clinical outcomes were favorable with conservative treatment. No evidence of tumor seeding in the needle track was reported and no PEI-related mortality observed. Conclusions. PEI is a safe neoadjuvant therapy for HCC on waiting list liver transplant candidates. In our series, pain and self-limited fever were the most frequent complications. Clinically significant severe complications were uncommon, and nonconservative treatments were not required.
引用
收藏
页码:3871 / 3873
页数:3
相关论文
共 16 条
[1]
BOUCHER E, 1998, GASTROENTEROL CLIN B, V22, P559
[2]
Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[3]
DiStasi M, 1997, SCAND J GASTROENTERO, V32, P1168
[4]
PERCUTANEOUS ETHANOL INJECTION FOR THE TREATMENT OF SMALL HEPATOCELLULAR-CARCINOMA - STUDY OF 95 PATIENTS [J].
EBARA, M ;
OHTO, M ;
SUGIURA, N ;
KITA, K ;
YOSHIKAWA, M ;
OKUDA, K ;
KONDO, F ;
KONDO, Y .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1990, 5 (06) :616-626
[5]
Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: A safe and effective bridge to liver transplantation [J].
Fontana, RJ ;
Hamidullah, H ;
Nghiem, H ;
Greenson, JK ;
Hussain, H ;
Marrero, J ;
Rudich, S ;
McClure, LA ;
Arenas, J .
LIVER TRANSPLANTATION, 2002, 8 (12) :1165-1174
[6]
The role of tumor ablation in bridging patients to liver transplantation [J].
Johnson, EW ;
Holck, PS ;
Levy, AE ;
Yeh, MM ;
Yeung, RS .
ARCHIVES OF SURGERY, 2004, 139 (08) :825-829
[7]
HEPATOCELLULAR-CARCINOMA AND CIRRHOSIS IN 146 PATIENTS - LONG-TERM RESULTS OF PERCUTANEOUS ETHANOL INJECTION [J].
LIVRAGHI, T ;
GIORGIO, A ;
MARIN, G ;
SALMI, A ;
DESIO, I ;
BOLONDI, L ;
POMPILI, M ;
BRUNELLO, F ;
LAZZARONI, S ;
TORZILLI, G ;
ZUCCHI, A .
RADIOLOGY, 1995, 197 (01) :101-108
[8]
Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation [J].
Llovet, JM ;
Mas, X ;
Aponte, JJ ;
Fuster, J ;
Navasa, M ;
Christensen, E ;
Rodés, J ;
Bruix, J .
GUT, 2002, 50 (01) :123-128
[9]
Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation [J].
Llovet, JM ;
Fuster, J ;
Bruix, J .
HEPATOLOGY, 1999, 30 (06) :1434-1440
[10]
Experience with radiofrequency ablation of small hepatocellular carcinomas before liver transplantation [J].
Pulvirenti, A ;
Garbagnati, F ;
Regalia, E ;
Coppa, J ;
Marchiano, A ;
Romito, R ;
Schiavo, M ;
Fabbri, A ;
Burgoa, L ;
Mazzaferro, V .
TRANSPLANTATION PROCEEDINGS, 2001, 33 (1-2) :1516-1517